Mode
Text Size
Log in / Sign up
N/A N=17

Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy

Hemophilia

Enrolled (actual)
17
Serious AEs
Results posted
Dec 2015
Primary outcome: Primary: Assessment of Bilateral Index of Maximal Peak Force — -40.86 percentage

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Patients with haemophilia (Other)
Age
Adult · 18+ yrs
Sex
Male
Sponsor
Universidad Católica San Antonio de Murcia
Primary completion
Oct 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Assessment of Bilateral Index of Maximal Peak Force
-40.86
PRIMARY
Assessment of Bilateral Index of Rate of Development During the Preparation Phase
31.34
PRIMARY
Assessment of Bilateral Index of Rate of Development During the Acceleration Phase
20.05
PRIMARY
Assessment of Maximal Peak Force
15.67
PRIMARY
Assessment of Rate of Development During the Preparation Phase
6190.86
PRIMARY
Change of Joint Condition Based on Clinical Assessment
4.88; 3.00; 5.82; 6.35
PRIMARY
Assessment of Rate of Development During the Acceleration Phase
8945.25
PRIMARY
Assessment of Maximal Velocity of Movement
0.48
SECONDARY
Weight of the Patients With Haemophilia
73.48
SECONDARY
Diagnosis, Severity of Hemophilia, Treatment (Prophylactic or on Demand)
15; 2; 7; 5; 5; 8
SECONDARY
Joint Bleeding Before the Assessment
7
SECONDARY
Height of the Patients With Haemophilia
176.53
SECONDARY
Body Mass Index of Patients With Haemophilia
23.36
SECONDARY
Age of Patients With Haemophilia
32.47

Summary

Trial to assess the bilateral deficit phenomenon during dynamic plantar flexion task in patients with haemophilic arthropathy Describe the differences in terms of the physical variables (muscular strength, range of motion and proprioception) in patients with hemophilia who have conducted a home treatment with a digital tool. Bookmark the relationship between clinical history of joint bleeds and clinical manifestations in standing and walking.

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed with hemophilia A and B.
  • With or without joint involvement clinically diagnosed, and with or without a previous history of hemarthrosis joint load legs.
  • In prophylactic regimen with FVIII / FIX concentrates .
  • Residents in the Autonomous Community of the Region of Murcia.

Exclusion Criteria

  • Patients without walking ability.
  • Patients diagnosed with other congenital coagulopathy (von Willebrand disease, etc..).
  • Patients with neurological or cognitive impairments that prevent understanding the questionnaires and physical tests.
  • Patients whose parents or guardians have not signed the informed consent document.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02165462). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search